Azosemide

Azosemide

SCHEMBL4421865

NS(=O)(=O)c1cc(-c2nnn[nH]2)c(NCc2cccs2)cc1Cl.NS(=O)(=O)c1cc(-c2nnn[nH]2)c(NCc2cccs2)cc1Cl

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 1/20 0.70
PDE3A Q14432 1/20 0.70
CISD1 Q9NZ45 4/20 0.58
POLB P06746 1/20 0.40
CA1 P00915 9/20 0.38
CA2 P00918 9/20 0.38
CA12 O43570 7/20 0.38
CA9 Q16790 7/20 0.38
CA7 P43166 4/20 0.38
CA5B Q9Y2D0 4/20 0.38
CA5A P35218 3/20 0.38
CA6 P23280 3/20 0.38
CA14 Q9ULX7 3/20 0.38
ALDH1A1 P00352 1/20 0.38
HTR1A P08908 1/20 0.38
CA4 P22748 1/20 0.38
HSD11B1 P28845 1/20 0.38
SLC10A1 Q14973 1/20 0.38
GPR35 Q9HC97 1/20 0.38
ABCG2 Q9UNQ0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Azosemide SCHEMBL48976 1.00 PDE4D (0.70) PDE4DPDE3ACISD1POLBCA1
Azosemide SCHEMBL30754398 1.00 PDE4D (0.70) PDE4DPDE3ACISD1POLBCA1
Azosemide SCHEMBL8988688 0.99 PDE4D (0.69) PDE4DPDE3ACISD1POLBCA1
Azosemide SCHEMBL230626 0.93 PDE4D (0.62) PDE4DPDE3ACISD1POLBCA1
Azosemide SCHEMBL231405 0.90 PDE4D (0.58) PDE4DPDE3ACISD1POLBCA1
Azosemide SCHEMBL230300 0.89 PDE4D (0.57) PDE4DPDE3ACISD1POLBCA1
SCHEMBL11929680 0.89 PDE4D (0.55) PDE4DPDE3ACISD1POLBALDH1A1
SCHEMBL12522802 0.88 PDE4D (0.55) PDE4DPDE3ACISD1ALDH1A1PTGS2
SCHEMBL10281116 0.87 PDE4D (0.54) PDE4DPDE3ACISD1POLBALDH1A1
SCHEMBL14513929 0.87 PDE4D (0.53) PDE4DPDE3ACISD1POLBCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544711-B2 Use of nitroderivatives in urinary incontinence NICOX S.A. (FR) 2009-06-09 US disclosed
US-20050101661-A1 Use of nitroderivatives in urinary incontinence NICOX S.A. (FR) 2005-05-12 US disclosed
EP-1473288-A1 Nitric ester derivatives of COX-2 inhibitors and their use for treating inflammation and cardiovascular diseases Nicox S.A. (FR) 2004-11-03 EP disclosed
EP-1437132-A1 Use of nitric ester derivatives in the manufacture of a medicament for the treatment of gastrointestinal tumors Nicox S.A (FR) 2004-07-14 EP disclosed
US-20040082652-A1 Nitric ester derivatives and their use in treating gastrointestinal tumors NICOX S.A. 2004-04-29 US disclosed
EP-0931065-A2 NITRIC ESTER DERIVATIVES AND THEIR USE IN URINARY INCONTINENCE AND OTHER DISEASES NICOX S.A. (FR) 1999-07-28 EP disclosed
WO-1998009948-A2 NITRIC ESTER DERIVATIVES AND THEIR USE IN URINARY INCONTINENCE AND OTHER DISEASES NICOX S.A. (FR) 1998-03-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082652-A1 Nitric ester derivatives and their use in treating gastrointestinal tumors NOS1, PTGER1, NOS3 PDE4D 2044/4885PDE3A 125/4885CISD1 2678/4885
US-20050101661-A1 Use of nitroderivatives in urinary incontinence NR0B1, NOX1, AKR1C1 PDE4D 959/4885PDE3A 289/4885CISD1 1662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.